This page has beta status

BMBS COST Action BM0902
Network of experts in the diagnosis of myeloproliferative disorders (MPD)

The main objective of the Action is to facilitate and improve the accuracy of the diagnosis of MPD and related diseases in European countries. Philadelphia-negative myeloproliferative disorders (MPD) and related diseases are chronic blood diseases which had known little improvement in diagnosis and treatment for decades. In 2005 the discovery in Europe of the V617F mutation of JAK2 in MPD has renewed interest in these diseases. Since 2005, other mutations have been discovered in MPD and related diseases. New diagnosis tools will be designed and novel drugs will soon be tested. The objective of this COST Action, which regroups the main leaders in the field of MPD research, diagnosis and patient care, is to establish a European Network of experts in MPD and related diseases, MPD-EuroNet. This Action will formalize collaboration between European MPD experts in order to facilitate, optimize and standardize diagnosis and care for MPD patients in Europe. The network will centralize the diagnostic investigation of rare forms of MPD and related diseases.

(Descriptions are provided by the Actions directly via e-COST.)

General Information*

Chair of the Action:


Vice Chair of the Action:


Science officer of the Action:


Administrative officer of the Action:

Ms Ange Marie INA UWASE


Action Fact Sheet

Download AFS as .RTF

Memorandum of Understanding

Download MoU as PDF

Annual Progress Conference Report

Download Annual Progress Conference Report as PDF

Progress Report

Download Progress Report as PDF


Download Poster as PDF


Action website:

* content provided by e-COST.
Data is synchronised once per night.


Last updated: 02 May 2011 top of page